Irbesartan E Idroclorotiazide Aurobindo

Irbesartan, the active ingredient in Irbesartan E Idroclorotiazide Aurobindo, is an angiotensin II receptor blocker presented as a combination tablet with hydrochlorothiazide for oral use. It treats hypertension, often in adults who require both blood pressure reduction and diuretic therapy.

GNH USA supplies Irbesartan E Idroclorotiazide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure. - Hypertension: lowers systolic and diastolic pressure by blocking angiotensin II and increasing urinary sodium excretion. - Diastolic hypertension: specifically reduces elevated diastolic values through combined vasodilation and diuresis. - Hypertension with fluid retention: provides blood pressure control while reducing excess extracellular fluid.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Increased urination: due to the diuretic component. - Electrolyte imbalance: particularly low potassium levels. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Blood dyscrasias: rare blood cell abnormalities. - Severe hypotension: dangerously low blood pressure.

Before initiating therapy, consider the following safety measures. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Electrolyte assessment: regularly check potassium and sodium levels. - Renal function evaluation: assess creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Caution in elderly: increased sensitivity to blood pressure changes and electrolyte disturbances. - Avoid in severe hepatic impairment: limited data on safety. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan/HCTZ may interact with several medicines; review patient medication lists. Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - Lithium: increased lithium levels and toxicity. - ACE inhibitors or other ARBs: additive effects on blood pressure and renal function. - NSAIDs: can reduce antihypertensive efficacy and impair renal function. Moderate Interactions (Monitor Closely): - Other antihypertensives: may require dose adjustment to avoid hypotension. - Antidiabetic agents: diuretic effect may alter glucose control. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma levels. - Thiazide‑type diuretics: additive electrolyte disturbances. - Warfarin: potential alteration of INR, monitor coagulation status.